CLLS earnings date and last-quarter result: next report 2026-08-11, last quarter beat, P/E -4.23. Updated 2026-07-23.
Cellectis (CLLS) Research Hub
Cellectis (CLLS) trades on NASDAQ, FR in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 0.9665 USD (-1.38%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.23, market cap 0.29B. This hub links to the full technical, earnings and options research available for CLLS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, FR |
| Last close | 0.9665 USD (-1.38%) |
| 52-week range | 0.8808 USD – 3.57 USD |
| Trend regime | Range |
| 14-day RSI | 16.4 (Oversold) |
| Trailing P/E | -4.23 |
| Market cap | 0.29B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for CLLS
Covered Call on CLLS: how it works, illustrative setup around the real 0.9665 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CLLS: how it works, illustrative setup around the real 0.9665 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CLLS: how it works, illustrative setup around the real 0.9665 USD price, max profit/loss, breakeven and when to use it. Educational.
CLLS technical analysis: range, last 0.9665 USD, RSI 16.4, 52w range 0.8808 USD–3.57 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CLLS in?
Cellectis (CLLS) is classified under Healthcare (Biotechnology), listed on NASDAQ, FR.
Is CLLS in an uptrend or downtrend?
As of 2026-10-26, CLLS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CLLS's trailing P/E ratio?
CLLS's trailing P/E is -4.23, with a market cap of 0.29B. See the earnings research page for full valuation detail.
When does CLLS next report earnings?
CLLS is next scheduled to report earnings on 2026-08-11.